Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~To be eligible for inclusion into the study, a patient must meet the following criteria:~* Subject has clinically confirmed diagnosis of active AD;~* Subject has chronic pruritus related to AD;~* Subject has moderate to severe pruritus;~* Female subject is not pregnant or nursing during any period of the study.~Key Exclusion Criteria:~A patient will be excluded from the study if any of the following criteria are met:~* Subject has clinically infected AD;~* Subject has pruritus attributed to a cause other than AD;~* Subject has any clinically significant medical condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Difelikefalin 0.25 mg tablets plus TCS cream (Type: EXPERIMENTAL): Oral difelikefalin tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed.
- Difelikefalin 0.5 mg tablets plus TCS cream (Type: EXPERIMENTAL): Oral difelikefalin tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed.
- Placebo tablets plus TCS cream (Type: ACTIVE_COMPARATOR): Oral placebo tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
- Placebo tablets plus Vehicle cream (Part A only) (Type: PLACEBO_COMPARATOR): Oral placebo tablets administered twice daily. Vehicle cream applied by study subjects to skin lesions once a day until control is achieved, then as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).